RTX Stock Will Keep Rewarding Patient Investors

RTX remains a buy as defense demand lifts backlog 22% to $289B and shares are up 18% since late April. Q2 delivered 14% revenue growth (16% organic), 21% adjusted EPS growth, and improved free cash flow to $2.88B despite capacity constraints. The Raytheon segment led with 18% sales growth and major contract wins, while Pratt & Whitney and Collins Aerospace highlighted operational progress and innovation.

Analysis

The market should treat this less as a one-quarter earnings beat and more as a multi-year visibility event. A backlog this large matters because it reduces revenue gap risk and gives RTX leverage to push pricing on long-cycle defense work, but the real upside is only realized if management converts that demand into billings faster than cost inflation and supply-chain friction. In other words, the equity story is shifting from “more orders” to “higher quality of earnings,” which can support multiple resilience even if headline growth slows.

Competitive pressure should spill over to peers with overlapping missile, radar, and integrated air-defense exposure, especially LMT and NOC, because award momentum tends to compound into the next procurement round and sustainment phase. The less obvious beneficiaries are not the primes but the upstream vendors that solve bottlenecks in electronics, forgings, and propulsion parts; those suppliers gain leverage when a prime is capacity-constrained and needs guaranteed throughput. By contrast, any commercial aerospace weakness at Pratt/Collins would be a separate drag and can cap enthusiasm if defense strength is the only thing carrying the thesis.

The main bear case is execution, not demand: backlog does not equal cash, and if program phasing or supplier delays persist, the market will eventually punish the name for lower conversion efficiency. Over the next 1-3 months, the key catalyst is whether management can reaffirm margin expansion and FCF conversion; over 6-18 months, the thesis breaks if defense spending rotates away from replenishment and toward slower-moving platforms. Falsifiers are simple: two straight quarters of stalled FCF improvement, margin compression, or delayed contract awards relative to backlog growth.

Key Decisions for Investors

• Maintain an overweight in RTX on a 3-6 month view; buy pullbacks rather than chasing strength, because the setup is driven by backlog-to-cash conversion rather than immediate order surprises.
• Relative-value trade: long RTX / short LMT into the next budget and procurement cycle. RTX has the cleaner operating leverage story; the pair should work if defense spending stays strong but investors discriminate on execution.
• Set a hard watch item on RTX free cash flow conversion and segment margins over the next two quarters. If annualized FCF stalls below the current improvement trend or margins do not expand, reduce exposure.
• Consider a partial hedge with a short in a defense ETF proxy if you want to isolate RTX-specific execution alpha, since broad defense multiple expansion may otherwise dilute the signal.